I am a
Home I AM A Search Login

Papers of the Week

Papers: 28 Oct 2023 - 3 Nov 2023

2023 Nov 02

Clin Drug Investig


Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial.


Li XN, Xu HR, Cui E, Petersen KB, Ryding J, Ettrup A, Østergaard JB, Larsen F


Most evidence suggests that the pharmacokinetics of monoclonal antibodies (mAbs) are not meaningfully altered by patient characteristics, including racial/ethnic differences. Nevertheless, the pharmacokinetic profile of eptinezumab has not been evaluated in a Chinese population. This study was designed to confirm the hypothesis that the pharmacokinetic profile of the anti-calcitonin gene-related peptide mAb, eptinezumab, is similar in healthy Chinese individuals to that of healthy non-Asian individuals and non-Asian patients with migraine.